North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.410

-6.6%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don W Stone who wrote (39)	10/30/1996 5:46:00 PM
From: andy harrison	of 82

First off Don, Thanks for the compliment about me being bright. I really appreciate your kind words. The comment about Sturza being correct about NVX's efficacy is way out of line. The advisory panel decided that the efficacy of NVX's DTaP vaccine is perfectly acceptable for all shots. BioCentury (a very respected Biotech newpaper) accurately related what transpired at the meeting. NVX, IMHO, will get approval in the near future. Abbott Labs will pound the pavement with the SAFEST DTaP vaccine. The efficacy is fine. Lederle had less than a totally favorable time at the panel meeting. I am sure that Sturza will put his usual negative spin on NVX's milestone and trumpet Lederle. If you can get your hands on BioCentury Extra from 10.30.96 you will basically know the real deal. The data that some of the panel member were looking for the 4th shot will be completed by November. (According to NVX conference call). Remember what I said in the past.... DtaP -IPV is a winner and the Menigitis vaccines and Strep vaccines are huge. The long term holders in NVX will be the big winners. (IMHO)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next